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Blood pressure (BP) is significantly influenced by genetic factors; however, less than
3% of the BP variance has been accounted for by variants identified from genomewide association studies (GWAS) of primarily European-descent cohorts. Other genetic
influences, including gene-environment (GxE) interactions, may explain more of the
unexplained variance in BP. African Americans (AA) have a higher prevalence and earlier
age of onset of hypertension (HTN) as compared with European Americans (EA);
responses to anti-hypertensive drugs vary across race groups. To examine potential
interactions between the use of loop diuretics and HTN traits, we analyzed systolic (SBP)
and diastolic (DBP) blood BP from 1222 AA and 1231 EA participants in the Hypertension
Genetic Epidemiology Network (HyperGEN). Population-specific score tests were used
to test associations of SBP and DBP, using a panel of genotyped and imputed single
nucleotide polymorphisms (SNPs) for AA (2.9 million SNPs) and EA (2.3 million SNPs).
Several promising loci were identified through gene-loop diuretic interactions, although
no SNP reached genome-wide significance after adjustment for genomic inflation. In AA,
SNPs in or near the genes NUDT12, CHL1, GRIA1, CACNB2, and PYHIN1 were identified
for SBP, and SNPs near ID3 were identified for DBP. For EA, promising SNPs for SBP were
identified in ESR1 and for DBP in SPATS2L and EYA2. Among these SNPs, none were
common across phenotypes or population groups. Biologic plausibility exists for many of
the identified genes, suggesting that these are candidate genes for regulation of BP and/or
anti-hypertensive drug response. The lack of genome-wide significance is understandable
in this small study employing gene-drug interactions. These findings provide a set of
prioritized SNPs/candidate genes for future studies in HTN. Studies in more diversified
population samples may help identify previously missed variants.
Keywords: blood pressure, hypertension, loop diuretic, gene-drug interaction, genome-wide association, african
americans, european americans

INTRODUCTION
High blood pressure (BP) is the leading cause of death in the
United States, contributing to a wide spectrum of cardiovascular, cerebrovascular, and renal diseases (Chobanian et al., 2003).
In the United States, one in three adults has high BP, with a mortality rate of 18.3 per 100,000 individuals annually. Public health
costs due to hypertension (HTN) and its sequelae are approximately $51 billion per year (Roger et al., 2012). Among US
adults, the age-adjusted prevalence of HTN is 42.5% in African
Americans (AA), 26.1% for Mexican Americans, and 29.1% for
Non-Hispanic European Americans (EA). This disparity is greater
for HTN than for other cardiovascular risk factors including
dyslipidemia and diabetes (Fryar et al., 2010). In past years,
genetic studies of HTN and BP were largely limited to cohorts
of European ancestry. However, it is still unknown the extent to
which findings discovered in a European-based population are
applicable to other race/ethnic groups (Rosenberg et al., 2010).
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Although a moderate portion of the between-individual
variance of HTN-related traits are explained by genetic factors, identifying the loci responsible for BP regulation has
remained frustrating. The heritability of BP ranges from about
30–45% in pedigree data to as high as 60% in twin studies
(Biron et al., 1976; Feinleib et al., 1977; Rotimi et al., 1999;
Snieder et al., 2003; Hottenga et al., 2005; Mitchell et al.,
2005). Heritability estimates vary depending on the specific
trait (for example, systolic BP, diastolic BP, and HTN) and the
means by which these traits are ascertained. Heritability estimates derived from non-European cohorts are similar to or
higher than in European cohorts (Rotimi et al., 1999; Bochud
et al., 2005; Zhang et al., 2009). Yet despite the substantial
estimated heritability and sample size in excess of 200,000
subjects, common variants identified by genome-wide association (GWA) studies explain less than 3% of inter-individual
BP variation (International Consortium for BP GWAS et al.,
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2011). While the reasons for this “missing heritability” have
been explored in detail elsewhere (Manolio et al., 2009; Zhang
et al., 2010), it is important to consider that the majority
of GWA studies ascertain traits on the background of ongoing drug therapy. Therefore, in lieu of statistical models that
consider only the genetic main effects, analyses incorporating
gene-drug interactions may increase the yield for findings of
association.
According to guidelines recommended by the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment
of High BP, thiazide and thiazide-like diuretics should be considered first-line antihypertensive drug therapy for patients
with uncomplicated HTN in the absence of other “compelling” comorbid indications such as diabetes and heart failure (Chobanian et al., 2003). This recommendation was based
largely on the results of the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT)
in which use of a diuretic was associated with reduced incidence of heart failure compared to the angiotensin-converting
enzyme inhibitor and the calcium-channel blocker (ALLHAT
Collaborative Research Group, 2002). However, in addition
to the disparity in the prevalence of HTN, differences in
drug response have also been noted. For example, AfricanAmerican race is associated with significantly greater systolic
BP (SBP) and/or diastolic BP (DBP) responses to thiazide
and loop diuretics compared to European-American patients
in small studies (Chapman et al., 2002; Wu et al., 2005).
Population-based differences may be attributable, at least in
part, to differences in the genetic architecture of BP between
world populations. Therefore, current efforts attempting to
increase representation from other continental populations may
improve the generalizability of genetic studies to diverse patient
populations.
Loop diuretics such as furosemide and bumetanide lower
BP by blocking the action of the SLC12A1 (NKCC2) sodiumpotassium-chloride channel in kidney, resulting in decreased
reabsorption of sodium, potassium, and chloride, and hence
water, from the urine. Bartter’s Syndrome Type 1 was identified
by linkage analysis to be the result of homozygous or compound heterozygous non-functional mutations in the SLC12A1
gene; this rare disorder is characterized by neonatal hypotension, volume depletion, and increased risk for death (Simon
et al., 1996). Loop diuretics also inhibit the SLC12A5 (NKCC1),
a homolog that is more widely expressed in the brain (Kanaka
et al., 2001). The potential for genetic variants to modulate
drug response extends beyond the actual molecular targets
of the drug and may include variants in proteins controlling intestinal absorption, enzymatic biotransformation, binding to carrier proteins, and renal elimination (Vormfelde et al.,
2003).
Here we consider whether SNP-loop diuretic interactions play
a role in the genetic architecture of BP in African- and EuropeanAmerican families in the HyperGEN study. The identification of
genetic variants that affect drug response could help practitioners to individualize medical therapy with the goal of optimizing benefit and reducing adverse effects both within and across
populations.
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MATERIALS AND METHODS
STUDY SAMPLE

HyperGEN is a multicenter family-based study to research the
genetic causes of HTN and related conditions (Williams et al.,
2000). Hypertensive sibships were enrolled from four separate
field centers from 1995 to 2005: Minneapolis, MN; Salt Lake City,
UT; Forsyth County, NC; and Birmingham, AL. The available
dataset was derived from 1258 subjects in 467 African-American
families and 1270 subjects in 299 European-American families.
Subjects with missing covariates (age, sex, and body mass index
[BMI]) and/or drug exposure (loop diuretics) were excluded.
Individuals with HTN onset past age 60 or secondary to primary kidney disease were also excluded (Williams et al., 2000).
Given loop diuretics are frequently prescribed to control symptoms in patients with reduced left ventricular systolic function,
two analysis models were considered. For the primary analysis, we
used the “Continuous-Covariate” model which included left ventricular ejection fraction (LVEF) as a continuous covariate; 1222
subjects in 459 African-American families and 1231 subjects in
299 European-American families were available. To test for a possible confounding association between the uses of loop diuretics
in subjects with low LVEF, the secondary “All Subjects” model
included all subjects regardless of the availability or value of LVEF;
1249 subjects in 466 African-American families and 1267 subjects
in 299 European-American families were available. Supine BPs
and LVEF were measured as previously described (Williams et al.,
2000; Kizer et al., 2004). The institutional review board at each
field center gave approval for the study protocol and informed
consent procedure.
GENOTYPED AND IMPUTED DATA

Most of the African-American subjects (N = 1083) were genotyped using the Affymetrix Genome-wide Human SNP array
6.0 [909,622 SNPs; Birdseed Genotype Calling Algorithm (Korn
et al., 2008)]. The remaining African-American (N = 175) and
all 1270 European-American subjects were genotyped using the
Affymetrix Genome-wide Human SNP array 5.0 (443,816 SNPs;
Bayesian Robust Linear Model with Mahalanobis distance classifier [BRLMM] calling algorithm). Genomic data was quality
controlled separately by race and by array as follows: samples
were removed for quality-related problems; SNPs were removed if
monomorphic, identified as an Affymetrix “house-keeping” SNP,
missing chromosomal location, or located on a mitochondrial or
sex chromosome; PLINK (Purcell et al., 2007) was used to find
and correct all non-Mendelian inheritance errors (performed in
a dataset integrating both arrays for the AA datasets); and SNPs
with missing rates >5%, minor allele frequency <1%, or Hardy
Weinberg p-value <10−6 were excluded. An account of genotyped
SNPs remaining following quality control is shown in Supplement
Table 1.
Genotype imputation was performed separately within each
race by the HyperGEN Data Coordinating Center using the
post-quality controlled genotype data for HyperGEN AfricanAmerican (846,813 genotyped SNPs) and European-American
(358,327 genotyped SNPs) subjects. Data from unrelated AfricanAmerican individuals (200 with the lowest GWAS missing rate)
were chosen from a total of 467 African-American HyperGEN
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families to estimate the imputation model parameters. Using
MACH software and the estimated imputation model parameters, ∼3.01 million HapMap SNPs (release 22, phasing data,
“revised union” of CEU and YRI populations) were imputed
in the African-American cohort. For association analysis, we
used a dataset of 2,943,641 genotyped and imputed SNPs, after
excluding SNPs that had imputation quality measure (R2 ) < 0.3,
minor allele frequency <1%, or Hardy Weinberg p-value <10−6 .
Genotypes were similarly imputed in the European-American
cohort using ∼2.54 million HapMap SNPs (release 22, phasing
data, CEU population). We used a dataset of 2,367,693 genotyped
and imputed SNPs using the same exclusion criteria. Association
analyses were performed separately using genotyped and imputed
SNPs and then results combined; when both genotyped and
imputed data was available at any locus, the genotyped data
was retained preferentially. Genomic information was obtained
from the National Center for Biotechnology Information human
genome assembly (March 2006, build 36.1, hg18). A locus was
defined as a cluster of SNPs within 100kb of the SNP with the
lowest P-value in the region.
ANALYSIS APPROACH

Population characteristics were expressed as percentages or
mean ± standard deviation. The EIGENSOFT package (Patterson
et al., 2006) was used to estimate a set of 10 principal components (PCs) for the AA subjects from 382,671 SNPs (representing
the intersection of the Affymetrix Genome-Wide Human SNP
5.0 and 6.0 Array SNPs). The PCs were estimated from unrelated subjects chosen from each family; the 10 PC’s were then
predicted for the remaining subjects. Since HyperGEN is a family
study, a linear mixed model with a random polygenic component
was used to account for phenotypic correlations among relatives. We used GenABEL (Aulchenko et al., 2007) and ProbABEL
(Aulchenko et al., 2010) packages, components of the ABEL suite,
and performed a two-step score test approximation, following
the developer’s recommendation for the analysis of family data.
In the first step, GenABEL was used to run a polygenic model,
which provides maximum likelihood estimates (MLEs) of our
covariate effects (e.g., age, age2 , age3 , sex, BMI, and LVEF), residual variance, and variance-covariance matrix for the SBP (or
DBP) phenotype. Analyses of the African-American cohort also
included 10 principal components of the GWAS SNPs representing population substructure as a co-variate to control type I error
rates due to population stratification (Shriner et al., 2011). In
the second step, the score tests for SNP and medication main
effects (assuming an additive model), as well as their interaction
effects, were performed in ProbABEL using the MLE of the other
parameters created from the first step.
MERLIN also internally performs association analysis using
this two-step score approach and provides identical results for
the main effect, but it is more straightforward to use the ABEL
suite for interaction analysis. Because both the ABEL suite and
MERLIN take account for phenotypic correlation across family
members using the kinship matrix, they are more sophisticated
than a mixed effects model with random effect for family relatedness. For example, in a mixed model the phenotypic correlation of
half siblings is the same as the correlation of full siblings, whereas
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in the ABEL suite the correlation of half siblings is half the correlation of full siblings. The effect of loop diuretics was coded
as dummy variable (0/1), whose main effect was included along
with SNP-drug interaction effect in the association analysis for
SBP and DBP. For each SNP, the interaction effect coefficients
were tested in the presence of the SNP main effect and medication main effect. The exposure group consisted of subjects taking
loop diuretics, either alone or in combination with other antihypertensive drugs. The comparison group consisted of subjects
not taking loop diuretics, although other antihypertensive drugs
were permitted. A Wald test was computed to determine the significance using chi-squared statistics with one degree of freedom.
The “Continuous-Covariate” model included LVEF as a continuous covariate. Similarly, the “All Subjects” model was performed
using the entire cohort without consideration of the availability
or value of LVEF.
Quantile-quantile (QQ) plots were performed for each
race/trait combination to assess deviation from the normal distribution; the genomic control inflation (lambda) factor was
calculated. Manhattan plots were generated in SAS (Version 9.3,
SAS Institute, Cary, North Carolina, USA), with the y-axis indicating −log10 (P) values and the x-axis plots the physical position
of the SNPs in genomic order, by chromosome and chromosome position. Plots were created for the SNP main effect in the
presence of the medication main effect and interaction effect, as
well as for the interaction effect in the presence of the SNP and
medication main effects. Regional association plots were generated to highlight chromosomal regions with a clustering of SNPs
with suggestive association using LocusZoom software, available
at http://csg.sph.umich.edu/locuszoom/. The linkage disequilibrium (LD) (r2 ) was calculated from the hg18/HapMap Phase II
YRI population for AA and hg18/HapMap Phase II CEU population for EA. SNPs (circles) are colored according to their level of
LD of each SNP with the index SNP (purple diamond) selected
as the most significant SNP in the region. Gray points are SNPs
without available LD information.

RESULTS
Compared to the European-American cohort, the AfricanAmerican cohort tended to be older and more predominantly
female, with higher BMI, SBP, and DBP. Loop diuretics were used
by 96 (7.9%) African-American and by 48 (3.9%) EA subjects
(Table 1). LVEF was missing from 27 AA and 36 EA; these individuals were excluded from the “Continuous-Covariate” models
but included in the “All Subjects” models. The prevalence of low
EF (LVEF ≤45%) was low (3.8% in AA, and 3.2% in EA).
The QQ plots showed evidence of inflation, in particular for
the loop-SNP interaction terms for SBP analyses; Supplement
Figure 1 shows the unadjusted P-values (black circles) and Pvalues adjusted for the genetic inflation factor lambda (genomic
control, blue crosses). Association analysis results are shown in
Figures 1–4. Manhattan plots show the adjusted −log10 (P) values for both SBP (Figures 1 and 3) and DBP (Figures 2 and 4)
for both races. In each figure, the top Manhattan plot shows
the SNP main effect in the presence of the SNP-loop diuretic
interaction effect, and the bottom Manhattan plot shows the
SNP-loop diuretic interaction in the presence of the SNP main
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Table 1 | Descriptive statistics of the study population.∗
Characteristics

African-

European-

American Cohort American Cohort
Sample size, n

1222

1231

Male, n (%)

398 (33%)

613 (50%)

Loop diuretic use, n (%)

96 (7.9 %)

48 (3.9%)

Age, years

45 ± 13

50 ± 14

Body mass index, kg/m2

32.4 ± 7.9

29.3 ± 6.0

Systolic blood pressure, mm Hg

129 ± 22

123 ± 19

Diastolic blood pressure, mm Hg

74 ± 12

71 ± 10

Left ventricular ejection fraction, %

61 ± 8

62 ± 8

% EF ≥ 45

1175 (96.2%)

1192 (96.8%)

FIGURE 3 | Association Results for SBP for European Americans: Main
and Interaction Effects with Loop Diuretics.

*For “Continuous-Covariate” model. % EF ≥ 45, percent with left ventricular

ejection fraction ≥45%.

FIGURE 4 | Association Results for DBP for European Americans: Main
and Interaction Effects with Loop Diuretics.
FIGURE 1 | Association Results for SBP for African Americans: Main
and Interaction Effects with Loop Diuretics.

RACE-SPECIFIC ASSOCIATION WITH SBP AND DBP

FIGURE 2 | Association Results for DBP for African Americans: Main
and Interaction Effects with Loop Diuretics.

effect. SNPs selected for regional plotting were chosen based on
the strong clustering on the Manhattan plots, as well as for the
number of SNPs in that region that showed promising levels of
significance. Regional plots are shown in Figures 5–7. The topscoring SNPs for association with gene-medication interactions
in BP are shown for AA in Table 2 (P < 1 · 10−6 ) and for EA in
Table 3 (P < 1 · 10−5 ). Online Supplement Tables 2–3 show the
100 most highly ranked SNP-loop diuretic interactions per race.
Supplement Table 4 compares these top scoring SNPs from each
cohort and phenotype top allow cross-race comparisons.
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For the African-American cohort, there were 14 SNPs in 7 loci
with suggestive association with SBP (P < 1 · 10−6 ; Figure 1);
the SNP with the most promising P-value was rs7702688 (P =
2.39 · 10−7 ) which lies in a relative gene desert ∼0.77 Mb downstream of the NUDT12 gene and is in high pairwise LD with
many other SNPs with more modest association located at that
locus. Other promising SNPs with suggestive associations with
SBP in AA include rs1633278 (P = 5.59 · 10−7 ) near PYHIN1 on
chromosome 1, rs2729258 (P = 5.71 · 10−7 ) on chromosome 3
which lies ∼0.18 Mb downstream of the CHL1 gene, rs11744176
(P = 6.56 · 10−7 ) which is intragenic to GRIA1 on chromosome
5. Another cluster of SNPs on chromosome 10 with more modest
associations with SBP in AA are notable because they are within
CACNB2 (rs16916928; P = 1.81 · 10−6 ), a gene previously associated with cardiovascular traits (rs16916928; P = 1.81 · 10−6 ).
There were 6 SNPs in 2 loci with suggestive association with DBP
(P < 1 · 10−6 ; Figure 2). The SNP with the lowest P-value for
DBP in AA was rs2811944 (P = 1.53 · 10−7 ), located on chromosome 1 adjacent to the ID3 gene. Supplement Table 2 shows
evidence of strong clustering on chromosomes 3 and 5 (with
multiple SNPs in strong LD).
For the European-American cohort, a more permissive Pvalue <1 · 10−5 was considered given the relatively lower power
due to the fewer number of subjects exposed to loop diuretics
(3.9% vs. 7.9% in AA). There was one SNP with a promising association with SBP in EA (rs3020401, P = 9.51 · 10−6 ) in ESR1 on
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FIGURE 5 | Regional Plot Results for SBP for African Americans.

chromosome 6 (Figure 3). A greater number of SNPs, 49 SNPs in
5 loci, showed suggestive associations with DBP in the EuropeanAmerican cohort (P < 1 · 10−5 ; Figure 4). Among these SNPs
was rs3790481 (P = 2.93 · 10−6 ) in DEPDC1 on chromosome 1,
and rs6012061 (P = 4.06 · 10−6 ) residing in an intron in EYA2 on
chromosome 20.
No SNP showing strong interaction effect also demonstrated
suggestive main effects. It is also notable that a top-100 associated
SNP in one cohort/phenotype combination often showed weakened association for the other phenotype in the same cohort (see
Supplement Table 4). Corroborative evidence was less commonly
noted across race groups. A difference in minor allele frequencies
among top SNPs may explain, at least in part, the difference in
association across races for some SNPs. For example, rs2729258
on chromosome 3 which has an allele frequency of 0.43 in AA
(where P = 5.71 · 10−7 with SBP), has a frequency of only 0.06 in
EA where it showed no association (P = 0.64).
FOLLOW-UP SEX-STRATIFIED ANALYSES

Since genetic variants in ESR1 have been previously noted to
affect BP in a sex-specific manner, the “continuous-covariate”
model was repeated in analyses stratified by sex in only the
European-American cohort (males: n = 613; females: n = 618),
limiting the regions of interest to the 1 Mb regions surrounding

www.frontiersin.org

rs3020401. The resulting analyses showed that the association
for SBP was greater in European-American men (unadjusted
P = 4.1 · 10−7 for rs3020401) than women (top scoring SNP in
region with unadjusted P = 2.3 · 10−4 ). The association for DBP
in European-American men and women was weaker (unadjusted
P < 8.2 · 10−4 for both).
COMPARISON WITH ALL SUBJECTS MODEL

Secondary analyses were performed in order to test for a possible confounding association between the uses of loop diuretics in
subjects with low LVEF. In addition to the primary “ContinuousCovariate” models that analyzed data from subjects with available
LVEF as a continuous trait, “All Subjects” models were also
performed using the entire cohort (AA 1249 and EA 1267) without consideration of availability or value of LVEF. Compared
to our primary results, there were few differences noted in the
Manhattan and regional plots for the “All Subjects” analyses in
African- and European-Americans cohorts for either SBP or DBP.
In general, the overall clustering and trends of association were
preserved even if the specific top-scoring signals varied somewhat
at any particular locus. In the “All Subjects” model, there were 6
SNPs with suggestive associations clustered on chromosome 17
for SBP in EA that were not seen in the “Continuous-Covariate”
model. This locus is 0.15 Mb upstream of the CA10 gene which

December 2013 | Volume 4 | Article 304 | 5

de las Fuentes et al.

SNP-loop diuretic interactions in hypertension

FIGURE 6 | Regional Plot Results for DBP for European Americans, SBP and DBP for European Americans.

encodes a carbonic anhydrase ion channel, the target for a weak
diuretic that is more commonly used today to treat glaucoma and
altitude sickness.

DISCUSSION
The relationship between BP and the risk of cardiovascular disease mortality is continuous, consistent, and independent of other
risk factors (Lewington et al., 2002). Epidemiologic studies have
shown that even modest control of BP on the range of 2–5 mmHg
reduction can result in a significant decrease in cardiovascular disease mortality (Cook et al., 1995; Sacks et al., 2001; Whelton et al.,
2002). Therefore the identification of SNP-drug interactions for
HTN-related traits may identify optimal treatment strategies for
patients and regulatory pathways that can be exploited for future
drug development and/or personalized treatment of HTN in the
general population.
Despite recent GWA studies of HTN-related traits that have
included massive sample sizes, <3% of the inter-individual variation in BP has been explained by known (common) variants (Levy
et al., 2009; Newton-Cheh et al., 2009; International Consortium
for BP GWAS et al., 2011). Since blood pressure-related traits
are typically measured during ongoing drug therapy, consideration of SNP-drug interactions may identify additional target loci
associated with BP. Herein we report findings from an analysis
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of GWA data for SNP-loop diuretic medication interactions
in systolic and diastolic BPs in the biracial HyperGEN study
cohort. We have identified several promising SNPs for both SBP
and DBP in the African- and European-American cohorts. It
is noteworthy that among the SNPs with the most suggestive
interaction effects, none showed equally compelling main effects.
It is also notable that SNPs with strong interaction effects in
one race cohort rarely showed association in the other. Thus,
although none of the reported associations surpassed the stringent Bonferroni-adjusted genome-wide significance threshold
(P < 5 · 10−8 ), these biologically plausible results nonetheless
highlight the importance of evaluating related phenotypes in
diverse racial/ethnic cohorts as a strategy to increase the yield
for loci relevant to BP regulation and/or antihypertensive drug
response and to broaden the generalizability of future therapeutic
approaches to multiple patient populations.
Among genes with known associations with cardiovascular
traits is CACNB2 (rs16916928; P = 1.81 · 10−6 ) which has drugSNP interaction effect on SBP in the African-American cohort.
The CACNB2 gene encodes the β2 subunit of the L-type voltagegated calcium channel that is widely expressed in cardiovascular
tissue. A non-synonymous variant in CACNB2 has been shown
to be responsible for Brugada’s syndrome, a heritable sudden cardiac death syndrome (Antzelevitch et al., 2007). This calcium
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P-value

Beta

SNP-loop interaction effect

P-value

Adjusted

SNP main effect

SV2B-SLCO3A1

GRIA1

NUDT12

NUDT12

LIMCH1

CHL1-LOC402123

THSD7B

PYHIN1

ID3-MDS2

Nearby genes

1

7

1

1

1

2

1

1

5

SNPs per locus

2

6

10

12

rs6721026

rs3020401

rs10764387

rs12303986

44, 940, 236

130, 314, 492

23, 457, 184

152, 324, 737

200, 955, 742

68, 723, 493

Physical position

0.04

0.03

0.14

0.35

0.04

0.06

MAF

I

G

I

I

I

I

G/I

G

G

C

A

A

C

A1

A

A

A

G

G

A

A2

0.69

NA

0.92

0.99

0.79

0.83

R2

DBP

DBP

DBP

SBP

DBP

DBP

Trait

0.75
0.61
1.20

−0.43
−0.49
−3.04

1.30

1.19

−0.23

2.06

0.96

SE

0.86

Beta

−31.62
−25.38
22.77
13.43
33.16
−27.26

8.45 · 10−1
5.64 · 10−1
4.23 · 10−1
1.11 · 10−2
1.12 · 10−1

Beta

5.66

6.82

2.84

3.66

5.34

6.47

SE

4.06 · 10−6

3.28 · 10−6

6.15 · 10−6

9.51 · 10−6

5.29 · 10−6

2.93 · 10−6

P-value

Adjusted

SNP-loop interaction effect

3.73 · 10−1

P-value

Adjusted

SNP main effect

RIT2-EYA2

12

2

17

MSRB2-PTF1A
GPR133-SFSWAP

17

2

2

16

SNPs per locus

PIP4K2A-ARMC3-

ESR1

SPATS2L

DEPDC1

Nearby genes

frequency; SBP, systolic blood pressure; SE, standard error of the beta coefficient; SNP, single nucleotide polymorphism.

Bolded genes represent loci where SNPs are intragenic. A1, allele 1; A2, allele 2; beta, beta coefficient; Chrom, chromosome; DBP, diastolic blood pressure; G/I, genotyped vs. imputed SNP; MAF, minor allele

20

1

rs3790481

rs6012061

Chrom

RS number

Table 3 | SNPs with Suggestive Association (P-value ≤ 1 · 10−5 ) for SBP and DBP in European Americans; Interaction Effect in the Presence of the Main Effect.

frequency; SBP, systolic blood pressure, SE, standard error of the beta coefficient; SNP, single nucleotide polymorphism.

Bolded genes represent loci where SNPs are intragenic. A1, allele 1; A2, allele 2; beta, beta coefficient; Chrom, chromosome; DBP, diastolic blood pressure; G/I, genotyped vs. imputed SNP; MAF, minor allele

89, 884, 905

152, 895, 338

103, 676, 287

103, 162, 869

41, 351, 387

577, 574

137, 612, 734

157, 171, 831

Physical position

Chrom

RS number

Table 2 | SNPs with Suggestive Association (P-value ≤ 1 · 10−6 ) for SBP and DBP in African Americans; Interaction Effect in the Presence of the Main Effect.
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channel is also the target for the anti-hypertensive calcium channel blocker drugs. Variants in CACNB2 have been associated with
HTN traits in numerous, including multiracial, studies (Levy
et al., 2009; Ho et al., 2011; International Consortium for BP
GWAS et al., 2011; Kato et al., 2011; Lin et al., 2011; Wain
et al., 2011). CACNB2 SNPs were genotyped in the INternational
VErapamil SR-Trandolapril STudy-GENEtic substudy (INVESTGENES), a outcomes study including 5598 hypertensive patients
with coronary artery disease who were randomized to either a βblocker or a calcium channel blocker (Niu et al., 2010). There was
a greater risk of adverse outcomes in patients with a rare promoter
genotype (G/G, rs2357928) when randomized to the calcium
channel blocker vs. the β-blocker, a finding that was consistent in
European-, African- and Hispanic-American cohorts. Functional
assays showed a significant increase in promoter activity for the
rare allele. Since HTN is strongly tied to cardiovascular outcomes,
these findings add further evidence of physiologic importance of
this gene to cardiovascular traits. In the INVEST-GENES study,
only a borderline main effect was detected for rs2357928 in AA;
as in our study, rs16916928 was only associated with BP in AA
when considered in the context of loop diuretic therapy (Niu
et al., 2010). Notably, loop diuretics, by inhibiting the sodiumpotassium-chloride channel in the kidney, also increase urinary
calcium excretion (Rejnmark et al., 2003); thus, there is biologic plausibility linking diuretic use with SNPs in CACNB2 in
modulating BP regulation.
Among the SNPs with suggestive association for SBP in the
European-American cohort was rs3020401 (P-value = 9.51 ·
10−6 ), which is within the ESR1, a gene that encodes the estrogen
receptor α. Aside from well-described involvement in gynecologic malignancies and osteoporosis, ESR1 has also been implicated in mostly candidate gene studies of myocardial infarction,
ischemic heart disease risk, in-stent restenosis, sudden cardiac
death and age-related changes in left ventricular structure, often
with disparate associations in men and women (Ferrero et al.,
2003; Schuit et al., 2004; Peter et al., 2007; Aouizerat et al.,
2011). There are also examples of variants in ESR1 interacting with hormone replacement therapy to alter high-density
lipoprotein levels and atherosclerosis severity (Herrington et al.,
2002; Koivu et al., 2003). A handful of candidate-gene studies have associated genetic variants in ESR1 with BP-related
traits. The Victorian Family Heart Study (Ellis et al., 2004) and
Framingham Offspring Study (Peter et al., 2005) both identified ESR1 variants with sex-specific associations with SBP and
DBP, respectively, in EA. Furthermore, the GenSalt study, which
investigated the genetic determinants of BP response to lowand high-salt diet interventions in Han Chinese, also identified ESR1 variants associated with DBP in men, but not women
(Kelly et al., 2013). Therefore, in order to explore the possibility of a sex-specific interaction between SNPs in ESR1 and loop
diuretics, the current study performed additional analyses stratifying the European-American cohort by sex. The associations
detected, while less significant due to the smaller sample size,
were strongest in men. It is notable that mean ages of the women
in both the Victorian Family Heart Study and HyperGEN were
54 and 50 years, respectively; thus, we are not able to determine
whether the association between SBP and ESR1 would be stronger
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among post-menopausal (estrogen-deficient) women. Although
the mechanisms remain unclear, our results suggest that loop
diuretics interact with variants in the ESR1 gene to modulate SBP
and that these effects may be further influenced by sex and/or
estrogen status.
Among suggestive SNPs, other genes identified have less established roles in cardiovascular disease. The top-scoring drug-SNP
interaction for SBP in the African-American cohort is located
on chromosome 5 (rs7702688; P = 2.39 · 10−7 ) in a relative gene
desert ∼0.77 Mb downstream of the NUDT12 gene. NUDT12 is a
Nudix hydrolase, a class of enzymes that regulates levels of circulating diadenosine phosphates (Abdelraheim et al., 2003) which
have been shown to have vasoactive properties (Schluter et al.,
1994). SNPs in this region have shown marginal associations with
BP traits (Gene [database on the Internet] et al., 2013). Also
among the more novel findings of this study is an association
for SBP in the African-American cohort with SNPs intragenic to
GRIA1 (rs11744176; P = 6.56 · 10−7 ) which encodes the alphaamino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)type glutamate receptor, an ion channel receptor. The binding
of the neurotransmitter L-glutamate induces a conformational
change allowing the passage of sodium and calcium through the
channel, causing depolarization of the neuron. While GWA studies have detected borderline associations with longevity, healthy
aging, and sudden cardiac death (Aouizerat et al., 2011; Walter
et al., 2011), GRIA1 has not been identified in other GWA studies
of HTN or BP. However, the AMPA receptor has been implicated
in the control of fluid ingestion (De Gobbi et al., 2009), a determinant of BP regulation. Perhaps more intriguing, both loop and
thiazide diuretics have been shown to potentiate AMPA receptordependent ion channel activity by reducing intracellular chloride
concentrations in neurons, favoring depolarization (Yamada and
Tang, 1993; Sipila et al., 2009). AMPA activation in the hypothalamus increases vasopressin release, a hormone which causes both
water retention and vasoconstriction. Thus, there is biologic plausibility that genetic variants in the GRIA1 gene may modulate the
BP response to diuretics (Sladek et al., 1998).
Another interesting finding was identified only in analyses that
included all subjects regardless of the availability of the LVEF.
SNPs in CA10 interacted with loop diuretics to modulate SBP
in the European-American cohort. Carbonic anhydrases, such as
that encoded by CA10, function to buffer metabolic sources of
acid through reabsorption of bicarbonate, along with sodium and
chloride, from the urine (Epstein and Grant, 1977). Synergism
between loop diuretics and carbonic anhydrase inhibitors has
prompted the use of combination therapy in patients resistant to
diuresis (Ellison, 1991). In addition to volume overload, patients
with heart failure may experience metabolic acidosis which could
favor increased activity of carbonic anhydrases (Reddy et al.,
1988); therefore genetic variants that alter the activity of these
ion channels may in turn modulate the effectiveness of the loop
diuretics to excrete sodium and hence control BP.
SNPs in SPATS2L (spermatogenesis-associated serine-rich
protein 2-like) have also been associated with both SBP and DBP
in a Korean cohort (Hong et al., 2010, 2011). Likewise, SNPs in
EYA2 (eyes absent homolog 2) have been associated with HTN in
a Japanese cohort (Kato et al., 2008). Although the mechanisms
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by which these genes are associated with BP regulation remains
elusive, these findings are consistent with the present study where
SNPs in both SPATS2L and EYA2 showed suggestive interaction
associations with loop diuretics for DBP in AA. The top-scoring
SNP for DBP in AA is intragenic to the ID3 (inhibitor of differentiation 3) gene. This gene encodes a transcription factor that has
been found to be protective against atherosclerosis (Doran et al.,
2010; Owens et al., 2010); a common loss-of-function SNP in the
human ID3 gene has been linked increased carotid intima-media
thickness (Doran et al., 2010), an intermediate trait associated
with a variety of cardiovascular outcomes (Lorenz et al., 2006).
CHL1, a gene associated in this study with SBP in AA, is a known
tumor suppressor gene; CHL1 SNPs have been shown to associate with LDL in interaction models with statin use (Barber et al.,
2010).
Given the small proportion of subjects taking loop diuretics
in the AA, and in particular the EA cohorts, there was little expectation of finding genome-wide significant interactions
due to limited power. Nonetheless, these analyses have identified
several genes with promising associations notable for plausible
biologic contributions to BP regulation and/or antihypertensive
drug response. Given that more permissive thresholds were used
to identify suggestive genes in the present study, additional studies
are necessary to confirm the findings and to determine potential
mechanisms for a role in BP regulation. Our findings may also be
limited by not accounting for the use of non-loop diuretics in the
comparison group or for the use of combination antihypertensive
therapies in the exposure group. This may have further reduced
the power. It is also unclear to what degree lack of information
on dosage, duration of therapy, and/or medication compliance of
loop diuretic therapy may have influenced our results. While not
adjusting for LVEF strengthened the association of SNPs in CA10
which were not identified in the “Continuous-Covariate” model,
the prevalence of subjects with an LVEF <45% was low (77 of
1222 African-American and 39 of 1231 European-American subjects), thereby limiting the strength of any conclusions from these
analyses. However, since the majority of peaks were common
to both the “Continuous-Covariate” and “All Subjects” models,
associated loci are unlikely to be the result of bias introduced by
the correlation between loop diuretic use and left ventricular systolic dysfunction. In summary, genome-wide interaction analyses
that consider the impact of loop diuretic use, including SNP-loop
interactions, on BP traits may provide a prioritized set of SNPs
and candidate genes worthy of replication and validation in studies of HTN. Studies in more diversified population samples may
help identify previously missed variants. In the meantime, these
findings make an important contribution to the body of literature
aimed at eliminating race disparities through tailored medical
therapies.

AUTHOR CONTRIBUTIONS
Conception and design (Yun Ju Sung, D. C. Rao), administrative
support (D. C. Rao), provision of study materials, collection and
assembly of data (Steven C. Hunt, Donna K. Arnett, D. C. Rao),
data analysis and interpretation (Lisa de las Fuentes, Yun Ju Sung,
Karen L. Schwander, Sonia Kalathiveetil, D. C. Rao), manuscript
writing (Lisa de las Fuentes, Yun Ju Sung, Karen L. Schwander,

www.frontiersin.org

SNP-loop diuretic interactions in hypertension

Sonia Kalathiveetil), final review and approval of manuscript (all
authors). The subject matter of this paper formed part of Sonia
Kalathiveetil ’s M.S. thesis in the GEMS Program of Washington
University.

ACKNOWLEDGMENTS
We thank the participants of the HyperGEN Study. For a complete list of HyperGEN Investigators: http://www.biostat.wustl.
edu/hypergen/Acknowledge.html. HyperGEN: The Hypertension
Network is funded by cooperative agreements (U10) with NHLBI:
HL54471, HL54472, HL54473, HL54495, HL54496, HL54497,
HL54509, HL54515, and 2 R01 HL55673-12. The study involves:
University of Utah: (Network Coordinating Center, Field Center,
and Molecular Genetics Lab); Univ. of Alabama at Birmingham:
(Field Center and Echo Coordinating and Analysis Center);
Medical College of Wisconsin: (Echo Genotyping Lab); Boston
University: (Field Center); University of Minnesota: (Field Center
and Biochemistry Lab); University of North Carolina: (Field
Center); Washington University: (Data Coordinating Center);
Weil Cornell Medical College: (Echo Reading Center); National
Heart, Lung, & Blood Institute.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at:
http://www.frontiersin.org/journal/10.3389/fgene.2013.
00304/abstract

REFERENCES
Abdelraheim, S. R., Spiller, D. G., and McLennan, A. G. (2003). Mammalian
NADH diphosphatases of the Nudix family: cloning and characterization of
the human peroxisomal NUDT12 protein. Biochem. J. 374, 329–335. doi:
10.1042/BJ20030441
ALLHAT Collaborative Research Group. (2002). Major outcomes in high-risk
hypertensive patients randomized to angiotensin-converting enzyme inhibitor
or calcium channel blocker vs diuretic: the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288,
2981–2997. doi: 10.1001/jama.288.23.2981
Antzelevitch, C., Pollevick, G. D., Cordeiro, J. M., Casis, O., Sanguinetti, M. C.,
Aizawa, Y., et al. (2007). Loss-of-function mutations in the cardiac calcium
channel underlie a new clinical entity characterized by ST-segment elevation,
short QT intervals, and sudden cardiac death. Circulation 115, 442–449. doi:
10.1161/CIRCULATIONAHA.106.668392
Aouizerat, B. E., Vittinghoff, E., Musone, S. L., Pawlikowska, L., Kwok, P. Y., Olgin,
J. E., and Tseng, Z. H. (2011). GWAS for discovery and replication of genetic loci
associated with sudden cardiac arrest in patients with coronary artery disease.
BMC Cardiovasc. Disord. 11:29. doi: 10.1186/1471-2261-11-29
Aulchenko, Y. S., Ripke, S., Isaacs, A., and Van Duijn, C. M. (2007). GenABEL: an
R library for genome-wide association analysis. Bioinformatics 23, 1294–1296.
doi: 10.1093/bioinformatics/btm108
Aulchenko, Y. S., Struchalin, M. V., and Van Duijn, C. M. (2010). ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics
11:134. doi: 10.1186/1471-2105-11-134
Barber, M. J., Mangravite, L. M., Hyde, C. L., Chasman, D. I., Smith, J. D., McCarty,
C. A., et al. (2010). Genome-wide association of lipid-lowering response to
statins in combined study populations. PLoS ONE 5:e9763. doi: 10.1371/journal.pone.0009763
Biron, P., Mongeau, J. G., and Bertrand, D. (1976). Familial aggregation of blood
pressure in 558 adopted children. Can. Med. Assoc. J. 115, 773–774.
Bochud, M., Bovet, P., Elston, R. C., Paccaud, F., Falconnet, C., Maillard,
M., et al. (2005). High heritability of ambulatory blood pressure
in families of East African descent. Hypertension 45, 445–450. doi:
10.1161/01.HYP.0000156538.59873.86

December 2013 | Volume 4 | Article 304 | 9

de las Fuentes et al.

Chapman, A. B., Schwartz, G. L., Boerwinkle, E., and Turner, S. T. (2002).
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 61, 1047–1055. doi:
10.1046/j.1523-1755.2002.00200.x
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo,
J. L., et al. (2003). The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the
JNC 7 report. JAMA 289, 2560–2572. doi: 10.1001/jama.289.19.2560
Cook, N. R., Cohen, J., Hebert, P. R., Taylor, J. O., and Hennekens, C. H.
(1995). Implications of small reductions in diastolic blood pressure for
primary prevention. Arch. Intern. Med. 155, 701–709. doi: 10.1001/archinte.1995.00430070053006
De Gobbi, J. I., Beltz, T. G., Johnson, R. F., Menani, J. V., Thunhorst,
R. L., and Johnson, A. K. (2009). Non-NMDA receptors in the lateral
parabrachial nucleus modulate sodium appetite. Brain Res. 1301, 44–51. doi:
10.1016/j.brainres.2009.08.094
Doran, A. C., Lehtinen, A. B., Meller, N., Lipinski, M. J., Slayton, R. P.,
Oldham, S. N., et al. (2010). Id3 is a novel atheroprotective factor containing a functionally significant single-nucleotide polymorphism associated
with intima-media thickness in humans. Circ. Res. 106, 1303–1311. doi:
10.1161/CIRCRESAHA.109.210294
Ellis, J. A., Infantino, T., and Harrap, S. B. (2004). Sex-dependent association of
blood pressure with oestrogen receptor genes ERalpha and ERbeta. J. Hypertens.
22, 1127–1131. doi: 10.1097/00004872-200406000-00013
Ellison, D. H. (1991). The physiologic basis of diuretic synergism: its role in treating
diuretic resistance. Ann. Intern. Med. 114, 886–894. doi: 10.7326/0003-4819114-10-886
Epstein, D. L., and Grant, W. M. (1977). Carbonic anhydrase inhibitor side
effects. Serum chemical analysis. Arch. Ophthalmol. 95, 1378–1382. doi:
10.1001/archopht.1977.04450080088009
Feinleib, M., Garrison, R. J., Fabsitz, R., Christian, J. C., Hrubec, Z., Borhani, N.
O., et al. (1977). The NHLBI twin study of cardiovascular disease risk factors:
methodology and summary of results. Am. J. Epidemiol. 106, 284–285.
Ferrero, V., Ribichini, F., Matullo, G., Guarrera, S., Carturan, S., Vado, A., et al.
(2003). Estrogen receptor-alpha polymorphisms and angiographic outcome
after coronary artery stenting. Arterioscler. Thromb. Vasc. Biol. 23, 2223–2228.
doi: 10.1161/01.ATV.0000101181.81022.BF
Fryar, C. D., Hirsch, R., Eberhardt, M. S., Yoon, S. S., and Wright, J. D. (2010).
Hypertension, high serum total cholesterol, and diabetes: racial and ethnic
prevalence differences in U.S. adults, 1999-2006. NCHS Data Brief 1–8.
Gene [Database on the Internet], National Library of Medicine (Us), and National
Center for Biotechnology Information (2013). "“NUDT12 nudix (nucleoside
diphosphate linked moiety X)-type motif 12 [Homo sapiens (human)]".)]”.).
Herrington, D. M., Howard, T. D., Hawkins, G. A., Reboussin, D. M., Xu, J., Zheng,
S. L., et al. (2002). Estrogen-receptor polymorphisms and effects of estrogen
replacement on high-density lipoprotein cholesterol in women with coronary
disease. N. Engl. J. Med. 346, 967–974. doi: 10.1056/NEJMoa012952
Ho, J. E., Levy, D., Rose, L., Johnson, A. D., Ridker, P. M., and Chasman,
D. I. (2011). Discovery and replication of novel blood pressure genetic
loci in the Women’s Genome Health Study. J. Hypertens. 29, 62–69. doi:
10.1097/HJH.0b013e3283406927
Hong, K. W., Lim, J. E., Kim, Y. J., Cho, N. H., Shin, C., and Oh, B. (2010).
KARE Genomewide Association Study of Blood Pressure Using Imputed SNPs.
Genomics Inform. 8, 103–107. doi: 10.5808/GI.2010.8.3.103
Hong, K. W., Lim, J. E., and Oh, B. (2011). A regulatory SNP in AKAP13 is
associated with blood pressure in Koreans. J. Hum. Genet. 56, 205–210. doi:
10.1038/jhg.2010.167
Hottenga, J. J., Boomsma, D. I., Kupper, N., Posthuma, D., Snieder, H., Willemsen,
G., and De Geus, E. J. (2005). Heritability and stability of resting blood pressure.
Twin Res. Hum. Genet. 8, 499–508. doi: 10.1375/183242705774310123
International Consortium for Blood Pressure Genome-Wide Association Studies,
Ehret, G. B., Munroe, P. B., Rice, K. M., Bochud, M., Johnson, A. D., Chasman,
D. I., et al. (2011). Genetic variants in novel pathways influence blood pressure
and cardiovascular disease risk. Nature 478, 103–109. doi: 10.1038/nature10405
Kanaka, C., Ohno, K., Okabe, A., Kuriyama, K., Itoh, T., Fukuda, A., and Sato,
K. (2001). The differential expression patterns of messenger RNAs encoding
K-Cl cotransporters (KCC1,2) and Na-K-2Cl cotransporter (NKCC1) in the
rat nervous system. Neuroscience 104, 933–946. doi: 10.1016/S0306-4522(01)
00149-X

Frontiers in Genetics | Statistical Genetics and Methodology

SNP-loop diuretic interactions in hypertension

Kato, N., Miyata, T., Tabara, Y., Katsuya, T., Yanai, K., Hanada, H., et al. (2008).
High-density association study and nomination of susceptibility genes for
hypertension in the Japanese National Project. Hum. Mol. Genet. 17, 617–627.
doi: 10.1093/hmg/ddm335
Kato, N., Takeuchi, F., Tabara, Y., Kelly, T. N., Go, M. J., Sim, X., et al. (2011).
Meta-analysis of genome-wide association studies identifies common variants
associated with blood pressure variation in east Asians. Nat. Genet. 43, 531–538.
doi: 10.1038/ng.834
Kelly, T. N., Rebholz, C. M., Gu, D., Hixson, J. E., Rice, T. K., Cao, J., et al. (2013).
Analysis of sex hormone genes reveals gender differences in the genetic etiology of blood pressure salt sensitivity: the GenSalt study. Am. J. Hypertens. 26,
191–200. doi: 10.1093/ajh/hps018
Kizer, J. R., Arnett, D. K., Bella, J. N., Paranicas, M., Rao, D. C., Province,
M. A., et al. (2004). Differences in left ventricular structure between black
and white hypertensive adults: the hypertension genetic epidemiology network study. Hypertension 43, 1182–1188. doi: 10.1161/01.HYP.0000128738.
94190.9f
Koivu, T. A., Fan, Y. M., Mattila, K. M., Dastidar, P., Jokela, H., Nikkari, S. T., et al.
(2003). The effect of hormone replacement therapy on atherosclerotic severity
in relation to ESR1 genotype in postmenopausal women. Maturitas 44, 29–38.
doi: 10.1016/S0378-5122(02)00293-1
Korn, J. M., Kuruvilla, F. G., McCarroll, S. A., Wysoker, A., Nemesh, J., Cawley, S.,
et al. (2008). Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat. Genet. 40, 1253–1260.
doi: 10.1038/ng.237
Levy, D., Ehret, G. B., Rice, K., Verwoert, G. C., Launer, L. J., Dehghan, A., et al.
(2009). Genome-wide association study of blood pressure and hypertension.
Nat. Genet. 41, 677–687. doi: 10.1038/ng.384
Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., and Prospective
Studies Collaboration. (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million
adults in 61 prospective studies. Lancet 360, 1903–1913. doi: 10.1016/S01406736(02)11911-8
Lin, Y., Lai, X., Chen, B., Xu, Y., Huang, B., Chen, Z., et al. (2011). Genetic variations
in CYP17A1, CACNB2 and PLEKHA7 are associated with blood pressure and/or
hypertension in She ethnic minority of China. Atherosclerosis 219, 709–714. doi:
10.1016/j.atherosclerosis.2011.09.006
Lorenz, M. W., Von Kegler, S., Steinmetz, H., Markus, H. S., and Sitzer, M. (2006).
Carotid intima-media thickening indicates a higher vascular risk across a wide
age range: prospective data from the Carotid Atherosclerosis Progression Study
(CAPS). Stroke 37, 87–92. doi: 10.1161/01.STR.0000196964.24024.ea
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter,
D. J., et al. (2009). Finding the missing heritability of complex diseases. Nature
461, 747–753. doi: 10.1038/nature08494
Mitchell, G. F., Destefano, A. L., Larson, M. G., Benjamin, E. J., Chen, M. H., Vasan,
R. S., et al. (2005). Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study.
Circulation 112, 194–199. doi: 10.1161/CIRCULATIONAHA.104.530675
Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L.,
et al. (2009). Genome-wide association study identifies eight loci associated with
blood pressure. Nat. Genet. 41, 666–676. doi: 10.1038/ng.361
Niu, Y., Gong, Y., Langaee, T. Y., Davis, H. M., Elewa, H., Beitelshees, A.
L., et al. (2010). Genetic variation in the beta2 subunit of the voltagegated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy
GENEtic Substudy (INVEST-GENES). Circ. Cardiovasc. Genet. 3, 548–555. doi:
10.1161/CIRCGENETICS.110.957654
Owens, A. P. 3rd., Subramanian, V., Moorleghen, J. J., Guo, Z., McNamara, C. A.,
Cassis, L. A., et al. (2010). Angiotensin II induces a region-specific hyperplasia
of the ascending aorta through regulation of inhibitor of differentiation 3. Circ.
Res. 106, 611–619. doi: 10.1161/CIRCRESAHA.109.212837
Patterson, N., Price, A. L., and Reich, D. (2006). Population structure and eigenanalysis. PLoS Genet. 2:e190. doi: 10.1371/journal.pgen.0020190
Peter, I., Huggins, G. S., Shearman, A. M., Pollak, A., Schmid, C. H., Cupples,
L. A., et al. (2007). Age-related changes in echocardiographic measurements:
association with variation in the estrogen receptor-alpha gene. Hypertension 49,
1000–1006. doi: 10.1161/HYPERTENSIONAHA.106.083790
Peter, I., Shearman, A. M., Zucker, D. R., Schmid, C. H., Demissie, S., Cupples,
L. A., et al. (2005). Variation in estrogen-related genes and cross-sectional and

December 2013 | Volume 4 | Article 304 | 10

de las Fuentes et al.

longitudinal blood pressure in the Framingham Heart Study. J. Hypertens. 23,
2193–2200. doi: 10.1097/01.hjh.0000188728.66183.92
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., et al.
(2007). PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am. J. Hum. Genet. 81, 559–575. doi: 10.1086/519795
Reddy, H. K., Weber, K. T., Janicki, J. S., and McElroy, P. A. (1988). Hemodynamic,
ventilatory and metabolic effects of light isometric exercise in patients with
chronic heart failure. J. Am. Coll. Cardiol. 12, 353–358. doi: 10.1016/07351097(88)90405-6
Rejnmark, L., Vestergaard, P., Pedersen, A. R., Heickendorff, L., Andreasen, F.,
and Mosekilde, L. (2003). Dose-effect relations of loop- and thiazide-diuretics
on calcium homeostasis: a randomized, double-blinded Latin-square multiple
cross-over study in postmenopausal osteopenic women. Eur. J. Clin. Invest. 33,
41–50. doi: 10.1046/j.1365-2362.2003.01103.x
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D.,
Borden, W. B., et al. (2012). Heart disease and stroke statistics–2012 update:
a report from the American Heart Association. Circulation 125, e2–e220. doi:
10.1161/CIR.0b013e31823ac046
Rosenberg, N. A., Huang, L., Jewett, E. M., Szpiech, Z. A., Jankovic, I., and Boehnke,
M. (2010). Genome-wide association studies in diverse populations. Nat. Rev.
Genet. 11, 356–366. doi: 10.1038/nrg2760
Rotimi, C. N., Cooper, R. S., Cao, G., Ogunbiyi, O., Ladipo, M., Owoaje,
E., and Ward, R. (1999). Maximum-likelihood generalized heritability estimate for blood pressure in Nigerian families. Hypertension 33, 874–878. doi:
10.1161/01.HYP.33.3.874
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha,
D., et al. (2001). Effects on blood pressure of reduced dietary sodium
and the Dietary Approaches to Stop Hypertension (DASH) diet. DASHSodium Collaborative Research Group. N. Engl. J. Med. 344, 3–10. doi:
10.1056/NEJM200101043440101
Schluter, H., Offers, E., Bruggemann, G., Van Der Giet, M., Tepel, M., Nordhoff,
E., et al. (1994). Diadenosine phosphates and the physiological control of blood
pressure. Nature 367, 186–188. doi: 10.1038/367186a0
Schuit, S. C., Oei, H. H., Witteman, J. C., Geurts Van Kessel, C. H., Van
Meurs, J. B., Nijhuis, R. L., et al. (2004). Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291, 2969–2977. doi:
10.1001/jama.291.24.2969
Shriner, D., Adeyemo, A., and Rotimi, C. N. (2011). Joint ancestry and association testing in admixed individuals. PLoS Comput. Biol. 7:e1002325. doi:
10.1371/journal.pcbi.1002325
Simon, D. B., Karet, F. E., Hamdan, J. M., Dipietro, A., Sanjad, S. A., and Lifton,
R. P. (1996). Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is
caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat. Genet. 13,
183–188. doi: 10.1038/ng0696-183
Sipila, S. T., Huttu, K., Yamada, J., Afzalov, R., Voipio, J., Blaesse, P., and
Kaila, K. (2009). Compensatory enhancement of intrinsic spiking upon
NKCC1 disruption in neonatal hippocampus. J. Neurosci. 29, 6982–6988. doi:
10.1523/JNEUROSCI.0443-09.2009
Sladek, C. D., Badre, S. E., Morsette, D. J., and Sidorowicz, H. E. (1998).
Role of non-NMDA receptors in osmotic and glutamate stimulation of vasopressin release: effect of rapid receptor desensitization. J. Neuroendocrinol. 10,
897–903. doi: 10.1046/j.1365-2826.1998.00276.x
Snieder, H., Harshfield, G. A., and Treiber, F. A. (2003). Heritability of blood
pressure and hemodynamics in African- and European-American youth.
Hypertension 41, 1196–1201. doi: 10.1161/01.HYP.0000072269.19820.0D

www.frontiersin.org

SNP-loop diuretic interactions in hypertension

Vormfelde, S. V., Burckhardt, G., Zirk, A., Wojnowski, L., and Brockmoller,
J. (2003). Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further
research. Pharmacogenomics 4, 701–734. doi: 10.1517/phgs.4.6.701.
22817
Wain, L. V., Verwoert, G. C., O’reilly, P. F., Shi, G., Johnson, T., Johnson, A. D.,
et al. (2011). Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat. Genet. 43, 1005–1011. doi:
10.1038/ng.922
Walter, S., Atzmon, G., Demerath, E. W., Garcia, M. E., Kaplan, R. C., Kumari, M.,
et al. (2011). A genome-wide association study of aging. Neurobiol. Aging 32,
2109 e2115–2109 e2128. doi: 10.1016/j.neurobiolaging.2011.05.026
Whelton, P. K., He, J., Appel, L. J., Cutler, J. A., Havas, S., Kotchen, T. A., et al.
(2002). Primary prevention of hypertension: clinical and public health advisory from The national high blood pressure education program. JAMA 288,
1882–1888. doi: jsc20296 [pii]
Williams, R. R., Rao, D. C., Ellison, R. C., Arnett, D. K., Heiss, G., Oberman,
A., et al. (2000). NHLBI family blood pressure program: methodology and
recruitment in the HyperGEN network. Hypertension genetic epidemiology network. Ann. Epidemiol. 10, 389–400. doi: 10.1016/S1047-2797(00)0
0063-6
Wu, J., Kraja, A. T., Oberman, A., Lewis, C. E., Ellison, R. C., Arnett, D.
K., et al. (2005). A summary of the effects of antihypertensive medications on measured blood pressure. Am. J. Hypertens. 18, 935–942. doi:
10.1016/j.amjhyper.2005.01.011
Yamada, K. A., and Tang, C. M. (1993). Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents.
J. Neurosci. 13, 3904–3915.
Zhang, K., Weder, A. B., Eskin, E., and O’connor, D. T. (2010). Genome-wide
case/control studies in hypertension: only the ’tip of the iceberg’. J. Hypertens.
28, 1115–1123. doi: 10.1097/HJH.0b013e328337f6bc
Zhang, S., Liu, X., Yu, Y., Hong, X., Christoffel, K. K., Wang, B., et al. (2009).
Genetic and environmental contributions to phenotypic components of
metabolic syndrome: a population-based twin study. Obesity (Silver Spring) 17,
1581–1587. doi: 10.1038/oby.2009.125
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 29 August 2013; paper pending published: 20 September 2013; accepted: 10
December 2013; published online: 25 December 2013.
Citation: de Las Fuentes L, Sung YJ, Schwander KL, Kalathiveetil S, Hunt SC, Arnett
DK and Rao DC (2013) The role of SNP-loop diuretic interactions in hypertension across ethnic groups in HyperGEN. Front. Genet. 4:304. doi: 10.3389/fgene.
2013.00304
This article was submitted to Statistical Genetics and Methodology, a section of the
journal Frontiers in Genetics.
Copyright © 2013 de Las Fuentes, Sung, Schwander, Kalathiveetil, Hunt, Arnett
and Rao. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.

December 2013 | Volume 4 | Article 304 | 11

